This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CORV Correvio Pharma (CORV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Correvio Pharma Stock (NASDAQ:CORV) 30 days 90 days 365 days Advanced Chart Get Correvio Pharma alerts:Sign Up Key Stats Today's Range$0.42▼$0.4250-Day Range$0.39▼$0.4252-Week Range$0.21▼$2.79VolumeN/AAverage Volume5.35 million shsMarket Capitalization$27.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada. Read More Receive CORV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CORV Stock News HeadlinesCorvus Pharmaceuticals announces preclinical dataon soquelitinibNovember 14, 2024 | markets.businessinsider.comCorvus Pharmaceuticals options imply 17.7% move in share price post-earningsNovember 12, 2024 | markets.businessinsider.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 13 at 2:00 AM | Stansberry Research (Ad)An Overview of Corvus Pharma's EarningsNovember 12, 2024 | benzinga.comAtea Pharmaceuticals Advances in HCV Treatment DevelopmentNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals price target lowered to $75 from $80 at H.C. WainwrightNovember 8, 2024 | markets.businessinsider.comBuy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward ScenarioNovember 6, 2024 | markets.businessinsider.comOzempic, Wegovy creator Novo Nordisk started with a love story, owned by philanthropic foundationNovember 3, 2024 | msn.comSee More Headlines CORV Stock Analysis - Frequently Asked Questions How were Correvio Pharma's earnings last quarter? Correvio Pharma Corp (NASDAQ:CORV) released its quarterly earnings data on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to analyst estimates of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%. What other stocks do shareholders of Correvio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Correvio Pharma investors own include Inovio Pharmaceuticals (INO), NightHawk Biosciences (NHWK), SCYNEXIS (SCYX), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), Oncobiologics (OTLK) and Vaxart (VXRT). Company Calendar Last Earnings3/30/2020Today9/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CORV CIKN/A Webwww.correvio.com Phone604-677-6905FaxN/AEmployees133Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.18 million Net Margins-107.81% Pretax MarginN/A Return on Equity-2,128.82% Return on Assets-58.56% Debt Debt-to-Equity Ratio22.54 Current Ratio1.07 Quick Ratio0.95 Sales & Book Value Annual Sales$32.63 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-21.00Miscellaneous Outstanding Shares66,191,000Free FloatN/AMarket Cap$27.80 million OptionableOptionable Beta0.08 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CORV) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Correvio Pharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Correvio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
